Cys-MC-GGFG-Dxd -d5 TFA (Cys-MC-GGFG-Dxd-d 5 TFA) is the deuterium labeled Cys-MC-GGFG-Dxd. Cys-MC-GGFG-Dxd -d5 TFA is a conjugate of Cys and Deruxtecan. Cys-MC-GGFG-Dxd -d5 TFA is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd -d5 TFA can be used in cancer research [1] [2].
References:
[1]. Peng H. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers. Antib Ther. 2021 Oct 15;4(4):222-227.
[2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.
References:
[1]. Peng H. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers. Antib Ther. 2021 Oct 15;4(4):222-227.
[2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.